Skip to main content

Abbvie Inc(ABBV-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low200.92
Day High206.20
Open:204.01
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly's and Novo's GLP-1 Duopoly
Newswire.ca
AbbVie and BioLabs Team Up to Support Life Sciences Innovation in Canada
Zacks Investment Research
Will AbbVie's Oncology Franchise Weigh on Q1 Top-line Growth?
Will AbbVie's Oncology Franchise Weigh on Q1 Top-line Growth?
Motley Fool
The Best High-Yield Dividend Stocks to Buy for 2026 and Beyond
Motley Fool
3 Stocks I Plan to Hold for the Next 20 Years
Motley Fool
The Psychedelic Revolution in Mental Healthcare
Zacks Investment Research
AbbVie Trades Below 50-Day and 200-Day SMA: How to Play the Stock
AbbVie Trades Below 50-Day and 200-Day SMA: How to Play the Stock
Tipranks
AbbVie’s Head-to-Head Psoriasis Study Sets Up New Catalyst for ABBV Investors
Tipranks
AbbVie Steps Deeper Into Obesity Market With New Phase 1 ABBV-295 Trial
Tipranks
AbbVie’s Real‑World HCV Study: What G/P Safety Data Could Mean for ABBV Investors
Motley Fool
Why AbbVie Is a No-Brainer Stock to Buy on the Dip
Tipranks
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), McKesson (MCK) and Regeneron (REGN)
Tipranks
Piper Sandler Sticks to Its Buy Rating for AbbVie (ABBV)
StockStory
1 Value Stock Worth Your Attention and 2 That Underwhelm
REYN
Stock Target Advisor
Stocks Hover for Direction as CPI Surges: Market Analysis: April 10th, 2026
Stocks Hover for Direction as CPI Surges: Market Analysis: April 10th, 2026
Tipranks
AbbVie’s ABBV-438 Myeloma Trial: Early-Stage Bet on Long-Term Oncology Growth
Motley Fool
3 High-Yielding Dividend Stocks to Buy, Even If You're Worried About the Market
Motley Fool
Could AbbVie Crash Lilly's Weight‑Loss Party?
Motley Fool
This Indicator Has Called Every Recession Over the Last 80 Years. Here's What It's Saying Now.
StockStory
2 S&P 500 Stocks with Solid Fundamentals and 1 We Brush Off
KDP
Zacks Investment Research
Will AbbVie's Neuroscience Franchise Aid Top-line Growth in Q1?
Will AbbVie's Neuroscience Franchise Aid Top-line Growth in Q1?
Motley Fool
S&P 500 Index Dividend Yields Are Teasing All-Time Lows. Here Are 3 Dividend Darlings That Crush This Trend.
Tipranks
AbbVie (ABBV) Receives a Buy from RBC Capital
Zacks Investment Research
Battle of Big Pharma: Is AbbVie Stock Pulling Ahead of Pfizer?
Battle of Big Pharma: Is AbbVie Stock Pulling Ahead of Pfizer?
StockStory
3 Market-Beating Stocks with Competitive Advantages
ABBV
Motley Fool
Could Buying This Dividend Pharma Stock Today Set You Up for Life?
MarketBeat
3 Dividend Aristocrats Whose Yields Can Help Combat Inflation
MarketBeat.com
MarketBeat
3 Companies Aggressively Raising Dividends While Others Play Defense
MarketBeat.com
Motley Fool
This Investor's $5 Million ETF Buy Pushes 2028 Bond Fund to Nearly 4% of AUM
Motley Fool
This Fund's Ladder Strategy Expanded With a $4 Million Buy in One 2027 Bond ETF
Motley Fool
Red Spruce Adds $3.35 Million to a 2029 Bond ETF With 4.5% Yield. Here's What Investors Should Know
StockStory
1 Healthcare Stock on Our Watchlist and 2 We Avoid
ABBV

Profile

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.